top of page

OncoMed completes patient enrollment in phase 2 trial of tarextumab in SCLC

OncoMed Pharmaceuticals has completed patient enrollment in the Phase 2 "PINNACLE" clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) for the treatment of small cell lung cancer (SCLC).

Click on this link for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page